On Monday, AIM ImmunoTech Inc (AMEX: AIM) was -3.57% drop from the session before settling in for the closing price of $0.28. A 52-week range for AIM has been $0.21 – $0.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -2.98% over the last five years. When this article was written, the company’s average yearly earnings per share was at 45.83%. With a float of $51.68 million, this company’s outstanding shares have now reached $57.14 million.
The firm has a total of 26 workers. Let’s measure their productivity. In terms of profitability, gross margin is -16.92%, operating margin of -15539.3%, and the pretax margin is -13952.74%.
AIM ImmunoTech Inc (AIM) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward AIM ImmunoTech Inc stocks. The insider ownership of AIM ImmunoTech Inc is 9.56%, while institutional ownership is 14.78%. The most recent insider transaction that took place on Sep 16 ’24, was worth 1,515. In this transaction CEO & President of this company bought 5,000 shares at a rate of $0.30, taking the stock ownership to the 1,493,042 shares. Before that another transaction happened on Sep 13 ’24, when Company’s CEO & President bought 20,000 for $0.31, making the entire transaction worth $6,160. This insider now owns 1,488,042 shares in total.
AIM ImmunoTech Inc (AIM) Recent Fiscal highlights
#####
According to the Wall Street analysts, stocks earnings will be around 45.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.00% during the next five years compared to 42.86% growth over the previous five years of trading.
AIM ImmunoTech Inc (AMEX: AIM) Trading Performance Indicators
You can see what AIM ImmunoTech Inc (AIM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 77.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.57, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of AIM ImmunoTech Inc (AIM)
Analysing the last 5-days average volume posted by the [AIM ImmunoTech Inc, AIM], we can find that recorded value of 0.4 million was better than the volume posted last year of 0.25 million. As of the previous 9 days, the stock’s Stochastic %D was 54.60%. Additionally, its Average True Range was 0.03.
During the past 100 days, AIM ImmunoTech Inc’s (AIM) raw stochastic average was set at 22.81%, which indicates a significant decrease from 47.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.76% in the past 14 days, which was higher than the 80.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3213, while its 200-day Moving Average is $0.3964. Now, the first resistance to watch is $0.2835. This is followed by the second major resistance level at $0.2971. The third major resistance level sits at $0.3113. If the price goes on to break the first support level at $0.2557, it is likely to go to the next support level at $0.2415. Now, if the price goes above the second support level, the third support stands at $0.2279.
AIM ImmunoTech Inc (AMEX: AIM) Key Stats
There are 51,496K outstanding shares of the company, which has a market capitalization of 15.43 million. As of now, sales total 200 K while income totals -28,960 K. Its latest quarter income was 50 K while its last quarter net income were -1,840 K.
